Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multi-Center, Open-Label, Single Administration, Sequential Dose Escalation of BIW-8405/MEDI-563 in Subjects With Mild Asthma

Next Previous
Trial Profile

A Multi-Center, Open-Label, Single Administration, Sequential Dose Escalation of BIW-8405/MEDI-563 in Subjects With Mild Asthma

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 15 Mar 2019

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Benralizumab (Primary)
  • Indications Asthma
  • Focus Adverse reactions

Most Recent Events

  • 11 Mar 2019 Results assessing pharmacokinetic (PK) data from nine clinical trials (NCT00512486, NCT00659659, NCT00768079, NCT00783289, NCT01238861, NCT01928771, NCT01914757, NCT02322775, NCT02075255) for patients with asthma, published in the Clinical Pharmacokinetics.
  • 26 Nov 2008 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
  • 07 Oct 2008 Interim results were reported at the European Respiratory Society meeting.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top